Data from 10‐year follow‐ups indicate that triple‐negative, HER2‐positive (HER2+), and HR+/HER2‐negative (HER2−) BC subtypes are more likely to develop BM.6, 7, 8. This evidence concerns the gene ERBB2 and breast cancer.